Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) has experienced a decline in its stock price by -7.21 compared to its previous closing price of 0.65. However, the company has seen a fall of -21.89% in its stock price over the last five trading days. globenewswire.com reported 2024-09-09 that ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company’s American Depositary Shares (ADSs), signaling their confidence in the company’s growth and direction.
Is It Worth Investing in Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) Right Now?
The stock has a 36-month beta value of 1.93. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for QNRX is 1.12M, and at present, short sellers hold a 1.10% of that float. On September 16, 2024, the average trading volume of QNRX was 474.78K shares.
QNRX’s Market Performance
The stock of Quoin Pharmaceuticals Ltd ADR (QNRX) has seen a -21.89% decrease in the past week, with a 25.27% rise in the past month, and a -16.49% fall in the past quarter. The volatility ratio for the week is 26.96%, and the volatility levels for the past 30 days are at 15.00% for QNRX. The simple moving average for the past 20 days is -7.04% for QNRX’s stock, with a -66.62% simple moving average for the past 200 days.
QNRX Trading at -2.09% from the 50-Day Moving Average
After a stumble in the market that brought QNRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.27% of loss for the given period.
Volatility was left at 15.00%, however, over the last 30 days, the volatility rate increased by 26.96%, as shares surge +20.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.73% upper at present.
During the last 5 trading sessions, QNRX fell by -21.89%, which changed the moving average for the period of 200-days by -86.64% in comparison to the 20-day moving average, which settled at $0.6519. In addition, Quoin Pharmaceuticals Ltd ADR saw -87.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNRX starting from Dunn Gordon, who purchase 20,000 shares at the price of $0.81 back on Sep 10 ’24. After this action, Dunn Gordon now owns 28,856 shares of Quoin Pharmaceuticals Ltd ADR, valued at $16,200 using the latest closing price.
Dunn Gordon, the Chief Financial Officer of Quoin Pharmaceuticals Ltd ADR, purchase 8,856 shares at $0.79 during a trade that took place back on Sep 09 ’24, which means that Dunn Gordon is holding 8,856 shares at $7,005 based on the most recent closing price.
Stock Fundamentals for QNRX
Current profitability levels for the company are sitting at:
- -56.75 for the present operating margin
- 0.34 for the gross margin
The net margin for Quoin Pharmaceuticals Ltd ADR stands at -53.75. The total capital return value is set at -0.87. Equity return is now at value -100.45, with -54.04 for asset returns.
Currently, EBITDA for the company is -9.25 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of -2.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.35.
Conclusion
To sum up, Quoin Pharmaceuticals Ltd ADR (QNRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
